Work

[Real world clinical data analysis of fuzuloparib for the treatment of ovarian epithelial cancer patients].

Year: 2025

Type: other

Source: PubMed

DOI: 10.3760/cma.j.cn112141-20241119-00614

Authors: D H Weng, J Jiang, Y J Yang, M Q Lu, J Y Bai, M Liu, X L Li, J Tian, Y T Guan, Q Li, L Chen, Q P Lyu, L X Ma, Y L Wang, H C Xu, H L Guo, L Sun, D Ma, Q L Gao

Institutions: Tongji Hospital, Huazhong University of Science and Technology, Shandong University, Qilu Hospital of Shandong University, Guiyang Medical University, Guizhou Cancer Hospital, Yichang Central People's Hospital, Shandong Provincial Hospital, Henan University, Henan University Huaihe Hospital and Huaihe Clinical Institute, Ningbo First Hospital, Xiangyang Central Hospital, Shandong Tumor Hospital, Beijing Hospital, Xingtai People's Hospital, People’s Hospital of Rizhao, Chinese Academy of Medical Sciences & Peking Union Medical College

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4413969904

Cites:

Cited by:

Related to: 10